ICP, a real estate development company that specializes in acquiring and revitalizing distressed properties, has its ...
today announced that the first subject has been dosed in the Phase III registrational trial of the Company's novel TYK2 (Tyrosine Kinase 2) inhibitor ICP-332 for the treatment of atopic dermatitis ...